BioNTech said on Friday that a new cancer immunotherapy candidate that it is working on with U.S. partner OncoC4 Inc. was shown to shrink tumors in close to 30% of participants in a mid-stage lung cancer trial.
Tag Archive for: Imjudo
The FDA approved AstraZeneca’s Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) and platinum-based chemotherapy Thursday for adult patients with metastatic non-small cell lung cancer (NSCLC).
The FDA greenlit AstraZeneca’s anti-CTLA-4 antibody tremelimumab in combination with its checkpoint inhibitor Imfinzi as a treatment for patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer.
